Why do immune cells inside a tumor stop fighting it?

We study the intricate interactions between cancer cells and the immune system, so that we can manipulate them to foster anti-tumoral responses.

Immunofluorescence image of a brain metastatic tumor
Immunofluorescence image of a brain metastatic tumor. Cancer cells are labelled in blue; immune cells in orange, yellow and pink.

Research

Our lab employs an interdisciplinary strategy to untangle the complexity of brain tumors, including the use of preclinical models of cancer, multi-omic analyses of patient samples and computational approaches.

Immunogenomic and aging determinants of therapy response

We study how genetics and aging shape the composition and phenotype of the immune microenvironment of brain metastatic tumors, with the long-term goal of developing personalized immunotherapies for patients with brain cancer.

Exploiting RNA sensing to treat primary and metastatic brain cancer

Can we manipulate anti-viral immunity to treat brain cancer? Our research in preclinical models showed that switching on an innate immune pathway normally used to fight viral infection can be effectively turned against glioblastoma.

Primary Central Nervous System Lymphoma (PCNSL)

PCNSL is a rare but aggressive cancer with limited treatment options and a high rate of relapse. We investigate why existing immunotherapies fail and evaluate novel immunomodulatory targets with therapeutic potential.

Latest news

All news

Selected publications

All publications
  1. Immunocompetent preclinical mouse models of brain cancer

    Álvarez-Prado ÁF.

    Methods Mol Biol 2026; 2959:165-177

  2. Cancer cell and microenvironmental rewiring by ADAR1 loss impairs glioblastoma tumor growth and extends survival

    Álvarez-Prado ÁF*, Hernández-Barranco A, Rentsch L, Costa CF, Joyce JA*.

    Cell Reports 2025; 44(9):116151

    * Co-corresponding authors.

  3. Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors

    Álvarez-Prado ÁF, Maas RR, Soukup K, Klemm F, Kornete M, (...), Joyce JA.

    Cell Reports Medicine 2023; 4(1):100900

  4. A broad atlas of somatic hypermutation allows prediction of activation-induced deaminase targets

    Álvarez-Prado ÁF, Pérez-Durán P, Pérez-García A, Benguria A, Torroja C, de Yébenes VG, Ramiro AR.

    Journal of Experimental Medicine 2018; 215(3):761-771

Funded by